Updates

Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress

JULY 21, 2017

Longeveron LLC is sponsoring a regenerative medicine symposium at the 2017 International Association of Gerontology and Geriatrics (IAGG) World Congress on July 25 in San Francisco.  The symposium, titled Regenerative Medicine Alternatives for Aging Conditions, will feature a global panel of physicians who are experts in stem cell therapy and geriatric conditions, such as Aging […]

learn more

Longeveron to Receive Grant from the Maryland Stem Cell Research Fund

MAY 22, 2017

MIAMI, Fl., May 22, 2017 – Longeveron announced receiving a $750,000 grant from the Maryland Stem Cell Research Fund (MSCRF) to continue groundbreaking stem cell research.  Longeveron, a Miami based regenerative medicine company, will partner with the University of Maryland and Johns Hopkins University to conduct a clinical trial for Hypoplastic Left Heart Syndrome (HLHS), […]

learn more

Longeveron Announces Publication of Phase 1 Safety and Efficacy Trial Results for Allogeneic Stem Cell Treatment in Frailty Patients

MAY 15, 2017

MIAMI, Fl., May 15, 2017 – Longeveron LLC, a leading regenerative medicine company developing innovative therapies for age-related diseases, announced the publication of Phase 1 safety, tolerability and efficacy data of its proprietary allogeneic mesenchymal stem cell (MSC) product in patients with Aging Frailty. The results were published on April 21st online in the Journals […]

learn more

Longeveron Begins Enrollment of Second Cohort of Phase 1 Trial of Allogeneic Mesenchymal Stem Cells to Treat Alzheimer’s Disease Patients

MAY 10, 2017

Data Monitoring Committee Confirms Safety and Recommends Trial Proceed   MIAMI, Fl., May 10, 2017 – Longeveron, a regenerative medicine company, today announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase. The clinical […]

learn more

STEM CELLS SHOW PROMISE IN THE TREATMENT OF FRAILTY

APRIL 14, 2017

BARCELONA, SPAIN, April 28, 2017. Stem cells from healthy young donors, delivered via intravenous infusion to frail older adults, were shown to reduce inflammation in a small pilot study reported today at the International Conference on Frailty and Sarcopenia Research (ICFSR). These findings suggest that stem cells may have the potential to reverse some of […]

learn more

Longeveron is Hosting a Satellite Symposium at the IAGG 2017 in San Francisco

APRIL 03, 2017

Longeveron’s symposium will be in Tuesday July 25 during lunch and will accommodate up to 125 attendees. This will include a panel presentation with some of the world experts on frailty. The theme for IAGG 2017, “Global Aging and Health: Bridging Science, Policy, and Practice,” will convene professionals from a variety of disciplines such as […]

learn more

Longeveron will be speaking at the International Conference on Frailty and Sarcopenia Research

APRIL 03, 2017

Longeveron will be speaking at the International Conference on Frailty and Sarcopenia Research in Barcelona, Spain on April 27-29, 2017. Learn more

learn more

Researchers Testing Stem Cells To Treat Alzheimer’s

APRIL 14, 2016

By Alexandria Hein In a first-of-its-kind clinical trial, researchers at the University of Miami Miller School of Medicine are using mesenchymal stem cells (MSCs) in an attempt to slow or reverse the symptoms of Alzheimer’s disease. The team is aiming to enroll 30 patients who will be tested and observed for cognitive function, memory, quality […]

learn more

Publications

Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty

Published by Oxford University Press on behalf of The Gerontological Society of America.

 

Background:

Impaired endogenous stem cell repair capacity is hypothesized to be a biologic basis of frailty. Therapies that restore regenerative capacity may therefore be beneficial. This Phase 1 study evaluated the safety and potential efficacy of intravenous, allogeneic, human mesenchymal stem cell (allo-hMSC)-based therapy in patients with aging frailty.